The long journey of TCL1 transgenic Mice: Lessons learned in the last 15 years

Gene Expression

Volumn 16, Issue 3, 2015, Pages 129-135

  Pekarsky, Yuri ^a   Drusco, Alessandra ^a   Kumchala, Prasanthi ^a   Croce, Carlo M ^a   Zanesi, Nicola ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

B Cell; Chronic lymphocytic leukemia (CLL); Em TCL1; Lck TCL1; Mouse models

Indexed keywords

B LYMPHOCYTE RECEPTOR; DACTINOMYCIN; INHIBITOR OF DIFFERENTIATION 4; INHIBITOR OF DIFFERENTIATION PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE LYN; PROTEIN KINASE SYK INHIBITOR; PROTEIN P53; RAG1 PROTEIN; UNCLASSIFIED DRUG; ONCOPROTEIN; TCL1 PROTEIN, MOUSE;

ANIMAL MODEL; B LYMPHOCYTE; CANCER INFILTRATION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DNA METHYLATION; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; HUMAN; MOUSE; NONHUMAN; ONCOGENE; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TCL1 ONCOGENE; TRANSGENIC MOUSE; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; GENETICS; LEUKEMIA, LYMPHOID; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

MUS; MUS MUSCULUS;

ANIMALS; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; LEUKEMIA, LYMPHOID; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS; T-LYMPHOCYTES;

EID: 84928385305     PISSN: 10522166     EISSN: None     Source Type: Journal    
DOI: 10.3727/105221615X14181438356256     Document Type: Review

References (53)

1. Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994; 91(26):12530-12534.
2. Pekarsky Y, Hallas C, Croce CM. The role of TCL1 in human T-cell leukemia. Oncogene 2001; 20(40):5638-56343.
3. Narducci MG, Virgilio L, Engiles jB, Buchberg AM, Billips L, Facchiano A, et al. The murine Tcl1 oncogene: Embryonic and lymphoid cell expression. Oncogene 1997; 15(8):919-926.
4. Virgilio L, Lazzeri C, Bichi R, Nibu K, Narducci MG, Russo G, et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA 1998; 95(7): 3885-3889.
5. Takizawa J, Suzuki R, Kuroda H, Utsunomiya A, Kagami Y, Joh T, et al. Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia. jpn j Cancer Res 1998; 89(7):712-718.
6. Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, Remotti D, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 2000; 60(8):2095-2100.
7. Hoyer KK, French SW, Turner DE, Nguyen MT, Renard M, Malone CS, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 2002; 99(22):14392-14397.
8. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99(10):6955-6960.
9. Zanesi N, Balatti V, Bottoni A, Croce CM, Pekarsky Y. Novel insights in molecular mechanisms of CLL. Curr Pharm Des 2012; 18(23):3363-3372.
10. Pekarsky Y, Zanesi N, Croce CM. Molecular basis of CLL. Sem Cancer Biol 2010; 20(6):370-376.
11. Simonetti G, Bertilaccio MT, Ghia P, Klein U. Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. Blood 2014; 124(7):1010-1019.
12. Zanesi N, Aqeilan R, Drusco A, Kaou M, Sevignani C, Costinean S, et al. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhe-matopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res 2006; 66(2):915-920.
13. Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 2000; 97(7):3028-3033.
14. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6(2):395-407.
15. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108(4):1334-1338.
16. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103(31):11713-11718.
17. Abrams ST, Lakum T, Lin K, jones GM, Treweeke AT, Farahani M, et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood 2007; 109(3):1193-1201.
18. Holler C, Pinon jD, Denk U, Heyder C, Hofbauer S, Greil R, et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: Validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009; 113(12):2791-2794.
19. Wu QL, Zierold C, Ranheim EA. Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia. Blood 2009; 113(13):3031-3039.
20. Giles RH, van Es jH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653(1):1-24.
21. Reya T, O'Riordan M, Okamura R, Devaney E, Willert K, Nusse R, et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000; 13(1):15-24.
22. Lucas DM, Edwards RB, Lozanski G, West DA, Shin jD, Vargo MA, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009; 113(19):4656-4666.
23. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. j Natl Cancer Inst 1991; 83(11):757-766.
24. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106(15):6250-6255.
25. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128(4):683-692.
26. Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX, et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2009; 106(32):13433-13438.
27. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115(3):755-764.
28. Enzler T, Kater AP, Zhang W, Widhopf GF, 2nd, Chuang HY, Lee J, et al. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114(20):4469-4476.
29. Gu Y, Chae HD, Siefring jE, jasti AC, Hildeman DA, Williams DA. RhoHGTPase recruits and activates Zap70 required for T cell receptor signaling and thymocyte development. Nat Immunol 2006; 7(11):1182-1190.
30. Sanchez-Aguilera A, Rattmann I, Drew DZ, Muller LU, Summey V, Lucas DM, et al. Involvement of RhoHGTPase in the development of B-cell chronic lymphocytic leukemia. Leukemia 2010; 24(1):97-104.
31. Scielzo C, Bertilaccio MT, Simonetti G, Dagklis A, ten Hacken E, Fazi C, et al. HS1 has a central role in the trafficking and homing of leukemic B cells. Blood 2010; 116(18):3537-3546.
32. Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F, et al. Loss of p53 and altered miR15-a/16-1short right arrowMCL-1 pathway in CLL: Insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia 2014; 28(1):118-128.
33. Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, et al. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 2011; 117(3):862-871.
34. Bertilaccio MT, Simonetti G, Dagklis A, Rocchi M, Rodriguez TV, Apollonio B, et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood 2011; 118(3):660-669.
35. Nganga VK, Palmer VL, Naushad H, Kassmeier MD, Anderson DK, Perry GA, et al. Accelerated progression of chronic lymphocytic leukemia in Emu-TCL1 mice expressing catalytically inactive RAG1. Blood 2013; 121(19):3855-3866, S1-16.
36. Lascano V, Guadagnoli M, Schot jG, Luijks DM, Guikema jE, Cameron K, et al. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. Blood 2013; 122(24):3960-3963.
37. Widhopf GF, 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proc Natl Acad Sci USA 2014; 111(2):793-798.
38. Reinart N, Nguyen PH, Boucas J, Rosen N, Kvasnicka HM, Heukamp L, et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood 2013; 121(5):812-821.
39. Fedorchenko O, Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P, Eckei L, et al. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood 2013; 121(20):4126-4136.
40. Zanesi N, Balatti V, Riordan J, Burch A, Rizzotto L, Palamarchuk A, et al. A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model. Blood 2013; 121(21):4355-4358.
41. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 2005; 436(7048):221-226.
42. Efanov A, Zanesi N, Nazaryan N, Santanam U, Palamarchuk A, Croce CM, et al. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia 2010; 24(5):970-975.
43. Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA 2012; 109(7):2555-2560.
44. DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013; 27(1):170-182.
45. Hofbauer JP, Heyder C, Denk U, Kocher T, Holler C, Trapin D, et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia 2011; 25(9):1452-1458.
46. Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM, et al. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood 2011; 118(23):6132-6140.
47. Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, et al. Overexpression of TCL1 activates the endoplasmic reticulum stress response: A novel mechanism of leukemic progression in mice. Blood 2012; 120(5):1027-1038.
48. Mittal AK, Chaturvedi NK, Rai KJ, Gilling-Cutucache CE, Nordgren TM, Moragues M, et al. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease. Mol Med 2014; 20(1):290-301.
49. Heinig K, Gatjen M, Grau M, Stache V, Anagnostopoulos I, Gerlach K, et al. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B cell activation and proliferation. Cancer Discov 2014.
50. Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010; 116(23):4894-4905.
51. Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, et al. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. Leukemia 2012; 26(12):2508-2516.
52. Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 2014; 123(8): 1207-1213.
53. Liu TM, Ling Y, Woyach jA, Beckwith K, Yeh YY, Hertlein E, et al. OSU-T315: A novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood 2014.